Observational studyObesity surgery2016
Intermittent Vagal Nerve Block for Improvements in Obesity, Cardiovascular Risk Factors, and Glycemic Control in Patients with Type 2 Diabetes Mellitus: 2-Year Results of the VBLOC DM2 Study.
Observational study in Obesity surgery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- Eating disinhibition and vagal tone moderate the postprandial response to glycemic load: a randomised controlled trial.Scientific reports · 2016Trial
- The autonomic nervous system in the regulation of glucose and lipid metabolism.Nature reviews. Endocrinology · 2026Review
- Central Nervous System Control of Glucose Homeostasis: A Therapeutic Target for Type 2 Diabetes?Annual review of pharmacology and toxicology · 2022Review
- Use of a bio-electronic device comprising of targeted dual neuromodulation of the hepatic and celiac vagal branches demonstrated enhanced glycemic control in a type 2 diabetic rat model as well as in an Alloxan treated swine model.Frontiers in neuroscience · 2022Article
- Potential Therapeutic Targeting Neurotransmitter Receptors in Diabetes.Frontiers in endocrinology · 2022Review
- Impact of the Hepatic Branch of the Vagus Nerve Transection in Laparoscopic Sleeve Gastrectomy for Patients with Obesity and Type 2 Diabetes Mellitus.Obesity surgery · 2021Article
- Electroceuticals in the Gastrointestinal Tract.Trends in pharmacological sciences · 2020Review
- Multi-channel intraneural vagus nerve recordings with a novel high-density carbon fiber microelectrode array.Scientific reports · 2020Article
- Chronic vagus nerve stimulation for drug-resistant epilepsy may influence fasting blood glucose concentration.Biomedical engineering online · 2020Article
- Vagal Nerve Stimulation for Glycemic Control in a Rodent Model of Type 2 Diabetes.Obesity surgery · 2019Article
- Standardization of Bariatric Metabolic Procedures: World Consensus Meeting Statement.Obesity surgery · 2019Article
- The vagus neurometabolic interface and clinical disease.International journal of obesity (2005) · 2018Review
- Invasive and Non-invasive Stimulation of the Obese Human Brain.Frontiers in neuroscience · 2018Review
- Brain stimulation in obesity.International journal of obesity (2005) · 2017Review
- Effects of sleeve gastrectomy plus trunk vagotomy compared with sleeve gastrectomy on glucose metabolism in diabetic rats.World journal of gastroenterology · 2017Article
- Earthquake Experience at Different Trimesters during Pregnancy Is Associated with Leukocyte Telomere Length and Long-term Health in Adulthood.Frontiers in psychiatry · 2017Article
- Novel developments in vagal afferent nutrient sensing and its role in energy homeostasis.Current opinion in pharmacology · 2016Review
- Role of the vagus nerve in the development and treatment of diet-induced obesity.The Journal of physiology · 2016Review
- Metabolism in mind: New insights into the 'gut-brain axis' spur commercial efforts to target it.Nature medicine · 2016Article
- Interventional treatment of obesity and diabetes: An interim report on gastric electrical stimulation.Reviews in endocrine & metabolic disorders · 2016Review
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOne-year results of the VBLOC DM2 study found that intermittent vagal blocking (VBLOC therapy) was safe among subjects with obesity and type 2 diabetes mellitus (T2DM) and led to significant weight loss and improvements in glycemic parameters and cardiovascular risk factors. Longer-term data are needed to determine whether the results are sustained.
methodsVBLOC DM2 is a prospective, observational study of 28 subjects with T2DM and body mass index (BMI) between 30 and 40 kg/m(2) to assess mid-term safety and weight loss and improvements in glycemic parameters, and other cardiovascular risk factors with VBLOC therapy. Continuous outcome variables are reported using mixed models.
resultsAt 24 months, the mean percentage of excess weight loss was 22% (95% CI, 15 to 28, p < 0.0001) or 7.0% total body weight loss (95% CI, 5.0 to 9.0, p < 0.0001). Hemoglobin A1c decreased by 0.6 percentage points (95% CI, 0.2 to 1.0, p = 0.0026) on average from 7.8% at baseline. Fasting plasma glucose declined by 15 mg/dL (95% CI, 0 to 29, p = 0.0564) on average from 151 mg/dL at baseline. Among subjects who were hypertensive at baseline, systolic blood pressure declined 10 mmHg (95% CI, 2 to 19, p = 0.02), diastolic blood pressure declined by 6 mmHg (95% CI, 0 to 12, p = 0.0423), and mean arterial pressure declined 7 mmHg (95% CI, 2 to 13, p = 0.014). Waist circumference was significantly reduced by 7 cm (95% CI, 4 to 10, p < 0.0001) from a baseline of 120 cm. The most common adverse events were mild or moderate heartburn, implant site pain, and constipation.
conclusionsImprovements in obesity and glycemic control were largely sustained after 2 years of treatment with VBLOC therapy with a well-tolerated risk profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.